Pharmaguy is a PharmaStar in Italy!
PharmaStar, which is an Italian on-line newspaper devoted entirely to the world of medicine, recently published a story tiled "Roche Pharma Italia conquista premio...
Social Media Listening by Pharma: Do the Ends Justify the Means?
This morning, I read with interest "The Value of Social Media Listening" by Alexandra Fulford, a ZS Business Consultant based in Zurich, Switzerland,
Alex focused...
Pharmaguy Steps Out on His Own
Today, Pharmaguy officially announced his "new" position as Chief Pundit at Pharmaguy.com. Like many other innovators in the pharmaceutical industry, pharmaguy -- working under...
J&J Joins the DOJ v Pharma Settlement Planetary System
The Department of Justice (DOJ) just updated its commemorative poster highlighting the now seven highest multi-million/billion dollar settlements that drug companies have agreed to...
My FDAdar Just Lit Up! Will This FDA Study Lead to Guidance on Advertising...
For nearly 4 years now, we pharma marketing aficionados and FDA watchers have been anxiously awaiting the promised guidelines on regulating pharmaceutical promotions on...
If Only I Could Download This Pharma Mobile Health App, I Would Be Able...
There are several stories out this morning about mobile health apps in general and pharma health apps in particular. (Keep reading to learn about...
Is Pharma “Gamification” Dead in the Water?
"Gamification" was a buzz word flitting around pharma circles (but not Google+ circles) a year or two ago. As an example, everyone I know...
FDA’s BadAd CE Program: There Should Be An App for This!
I just completed FDA's BadAd online course for healthcare professionals who can earn CE credits while learning how to identify potentially untruthful or misleading...
Just As I Suspected: Pharma Companies Set Up Google+ Ghost Towns
Eye On FDA's Mark Senak is keeping tabs on pharma's social media assets, including activity in Twitter, Facebook, YouTube, Pinterest and Google+. With regard...
FDA’s Expedited Approval of Drugs is Based on Trials of 104 Patients vs. 580...
According to a study published by JAMA Internal Medicine, 80% fewer patients were studied as part of expedited reviews of new drugs approved by...
